Royal colleges in the UK have received more than £9 million in marketing payments from drug and medical devices companies since 2015, but do not always disclose the payments publicly, finds an investigation published by ...
Jul 26, 2023
1
1
(HealthDay)—The incomes of U.S. doctors have grown less than the incomes of other health professionals over the past few decades, a new study indicates.
Nov 27, 2012
0
0
A national registry to capture all pharma/medical device industry payments and other benefits made to all clinicians, healthcare organizations and patient support groups should be set up as a matter of urgency in the UK, ...
Apr 19, 2021
0
3
From 2012 to 2016 the drug industry donated over £57 million to UK patient organisations, with priority given to a small number of organisations supporting commercially high profile conditions like cancer, reveals an analysis ...
May 22, 2019
0
2
A study suggests that safety-net hospitals (SNHs), which typically care for poor patients, performed more poorly than other hospitals on nearly every measure of patient experience and that could have financial consequences ...
Jul 16, 2012
0
0
The full impact of knee replacement surgery on both patients' lives and on society includes significant overall cost savings, according to a new study published in the Journal of Bone and Joint Surgery (JBJS). Researchers ...
Aug 21, 2013
0
0
The most powerful tool for combating COVID is not a drug or a vaccine, but a method. A randomized trial is the best way to discover what works and what doesn't. This method underlies much of the progress in modern medicine, ...
Aug 23, 2021
0
5
From research dollars to free lunches and junkets, drug and medical device companies paid doctors and leading hospitals nearly $6.5 billion last year, according to government data posted Tuesday.
Jun 30, 2015
0
12
(HealthDay)—Medicare will pay for a new, expensive cancer medication that costs about $178,000 for a standard course of treatment, the Obama administration says.
Aug 11, 2015
0
10
Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.
May 13, 2013
0
0
